Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal strong financial performance, strategic growth in Medicaid and Medicare Advantage, and disciplined capital deployment plans. Despite maintaining guidance, management's focus on AI and value-based care, along with a promising outlook on partnerships and MA growth, are positive indicators. The market cap suggests moderate sensitivity to news, leading to a prediction of a positive stock price movement of 2% to 8%.
Key Financial Performance
Implemented Providers 5,535 providers, a 13.6% increase year-over-year. Growth attributed to strong new provider signings and implementations.
Value-Based Attributed Lives 1.6 million lives, up 26.5% year-over-year. Growth driven by new provider growth and addition of the Evolent ACO business.
Practice Collections $914.8 million, a 14.6% increase year-over-year. Growth attributed to implemented provider growth, attribution growth, and value-based care performance.
Adjusted EBITDA $36.7 million, a 36.3% increase year-over-year. EBITDA margin expanded 290 basis points to 28.5%, highlighting significant operating leverage.
Cash Position $219.5 million in cash and no debt. Typical Q1 cash outflows included value-based care payments to providers and employee bonuses.
Commercial Attributed Lives 913,000 lives, a 17% increase year-over-year. Growth attributed to new provider growth and value-based care performance.
CMS Medicare Programs Attributed Lives 62% increase year-over-year. Growth attributed to new provider growth and value-based care performance.
Medicare Advantage Attribution 20% increase year-over-year. Growth attributed to new provider growth and value-based care performance.
Medicaid Attribution 36% increase year-over-year. Growth attributed to new provider growth and value-based care performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
National footprint expansion: Privia Health now operates in 24 states and the District of Columbia, with plans to expand further into existing and new states both organically and inorganically.
Attributed lives growth: Total attributed lives increased over 26% year-over-year, driven by new provider growth and the addition of the Evolent ACO business. Commercial attributed lives grew by 17%, CMS Medicare programs by 62%, Medicare Advantage by 20%, and Medicaid attribution by 36%.
Provider growth: Implemented providers grew 13.6% year-over-year to 5,535, caring for over 5.9 million patients.
Practice collections: Increased 14.6% year-over-year to $914.8 million, driven by provider growth and value-based care performance.
Adjusted EBITDA: Increased 36.3% year-over-year to $36.7 million, with EBITDA margin expanding 290 basis points to 28.5%.
Value-based care focus: Privia Health remains focused on increasing attribution and generating positive contribution margin across its value-based care book, aiming for consistent and sustainable earnings growth.
Guidance and financial discipline: Maintained 2026 guidance metrics, raised attributed lives guidance, and emphasized disciplined growth leveraging a strong balance sheet.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that its future financial and operating performance is subject to risks and uncertainties related to healthcare regulatory environments, which could materially impact results.
Market Expansion Risks: While the company plans to expand its presence in existing and new states, both organically and inorganically, there is a risk associated with executing these expansions effectively.
Attribution Growth Challenges: The company is highly focused on increasing attribution and generating positive contribution margins across its value-based book, which could pose challenges if growth targets are not met.
Economic and Cash Flow Risks: The company expects to become a full cash taxpayer, which could impact free cash flow conversion and financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Annual Guidance for 2026: Maintaining 2026 guidance across all metrics, with an increase in the range for attributed lives due to strong first-quarter attribution growth.
EBITDA Growth: Expected EBITDA growth of approximately 20% at the midpoint of the guidance, with 80% of EBITDA converting to free cash flow.
Attributed Lives: Attributed lives increased over 26% year-over-year, with commercial attributed lives up 17%, CMS Medicare programs up 62%, Medicare Advantage up 20%, and Medicaid attribution up 36%. Guidance range for attributed lives at year-end has been raised.
Market Expansion: Plans to expand presence in existing and new states, both organically and inorganically, leveraging balance sheet strength.
Pipeline and Business Development: Guidance assumes no new business development, but there is a robust pipeline of existing market expansion and new market opportunities.
EBITDA Growth Rate: Over the last 2 years, EBITDA growth rate averaged 32%. Achieving the midpoint of 2026 guidance will result in EBITDA more than doubling over the last 3 years.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why did the company maintain its outlook on most metrics despite a strong Q1?
A:The company maintained its outlook because it is still early in the year and prefers to adjust guidance as more data becomes available. They aim to execute consistently every quarter and will adjust guidance if trends continue positively. Shared savings are expected to grow year-over-year if current trends persist.
Q:What is the company's perspective on Medicare Advantage (MA) and its appetite for the business?
A:The company views MA as having strong tailwinds due to demographic changes over the next 5-15 years. They are focused on growing their MA book, which includes over 550,000 attributed lives. They prefer a shared risk model over full capitation to avoid conflicts of interest and believe their value proposition lies in low-cost, dense networks. They will continue to work with payers and adapt to geographic variations.
Q:Are there more opportunities for growth in the business development pipeline or M&A?
A:The company sees strong opportunities due to the dissipation of aggressive investments by VCs and private equity. They are focused on acquiring service entities, tech platforms, ACO entities, medical groups, and tax IDs to create dense medical groups and integrated platforms. They aim to deploy capital strategically and remain disciplined with valuations.
Q:How does the company view adding more specialty care to its network?
A:The company sees the addition of specialty care happening naturally as networks mature. They currently have a 60-40 mix of primary care to specialty care, trending towards 50-50. They focus on non-surgical specialties and see opportunities in moving surgeries to ASC settings. They aim to expand their strategy to include specialists as value-based arrangements evolve.
Q:What is the company's view on the new lead program from CMS?
A:The company is evaluating the new lead program but does not plan to move its MSSP ACO into lead due to the strong performance of MSSP. They believe CMS may converge elements of MSSP and lead over time. They are open to adding new providers and lives into lead in new geographies or through acquisitions.
Q:How does the company approach risk in the commercial attributed lives segment?
A:The company focuses on converting traditional fee-for-service payments into value-based arrangements. They take some risk on commercial lives to help payers manage MLR and are compensated through care management PMPM, quality-based bonuses, and shared savings. They avoid taking significant risk due to the open-access nature of commercial patients.
Q:What are the company's thoughts on technology and AI investments?
A:The company is excited about its new CTO and is focused on implementing AI across its tech stack in areas like corporate functions, care center operations, and care delivery. They aim to increase productivity, reduce costs, and improve margins. They are working with partners like Google Suite, Salesforce, and Snowflake to integrate AI into workflows.
Q:What drove the strength in shared savings revenue in Q1?
A:The strength in shared savings revenue was due to a mix of prior year performance adjustments and current year performance across the book, including commercial, MSSP, and MA. The company does not break down the exact contributions but notes consistent growth over a rolling 12-month basis.
Q:What is the company's strategy for Medicaid attributed lives?
A:The company sees organic growth in Medicaid attributed lives as part of its overall provider growth. They focus on value-based strategies to improve care for Medicaid populations but avoid taking downside risk due to the challenges in reimbursement and addressing the needs of low-income populations.
Q:How does the company view payer reforms on prior authorization policies?
A:The company believes prior authorization reforms are more relevant to acute settings than ambulatory care. They see minimal impact on their business and expect AI to help streamline prior authorization processes over time.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the breakdown of shared savings revenue contributions between prior year and current year performance, stating that it varies quarter-by-quarter. They also did not provide granular metrics on the sell-through of the full Privia platform into the physician base acquired from Evolent, citing early days in the integration process. Additionally, they did not elaborate on the exact impact of better Medicare Advantage rates on their different risk models, emphasizing that ground-level payer contracting remains consistent.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACO Commercial
Columbia provider
Communications comment
Conference Borchert
Incorporated Communications
Officer Chief
Promoter Score
Relations Incorporated
Score footprint
attribution momentum
bonus life
book goal
care margin
care organization
combination provider
country presence
development market
end guide
footprint momentum
goal physician
government contract
guide midpoint
implementation visibility
leverage cash
life attribution
life end
margin basis
midpoint cash
midpoint year
momentum care
opportunity balance
organization country
outflow value
point life
presence state
presentation result
provider addition
provider employee
question Vice
remainder provider
result Parth
retention Promoter
state balance
strength value
PRVA Transcript
Privia Health Group, Inc. (PRVA) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary and Q&A reveal strong financial performance, strategic growth in Medicaid and Medicare Advantage, and disciplined capital deployment plans. Despite maintaining guidance, management's focus on AI and value-based care, along with a promising outlook on partnerships and MA growth, are positive indicators. The market cap suggests moderate sensitivity to news, leading to a prediction of a positive stock price movement of 2% to 8%.
Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong financial metrics, optimistic guidance, and strategic acquisitions, like the Evolent ACO, likely to enhance future profitability. The company’s strategy to deploy capital for growth, coupled with raised guidance, indicates positive market sentiment. Despite some management evasiveness on specifics, the overall tone is confident, suggesting a stock price increase. Given the market cap of $2 billion, the reaction is expected to be moderately positive.
Privia Health Group, Inc. (PRVA) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance, optimistic guidance for 2025, and strategic growth in new markets. The Q&A section revealed positive analyst sentiment, with questions focusing on growth opportunities and market expansion. Despite some cautious language from management, the overall tone was positive. The company's strategic plan and guidance raise are expected to positively impact the stock price, especially given the small-cap nature of the company. The positive sentiment and strategic growth initiatives outweigh any concerns about cautious language or limited Q4 profitability growth.
Privia Health Group, Inc. (PRVA) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call summary and Q&A highlight strong financial performance, strategic growth, and optimistic guidance. Key positive factors include broad-based growth, effective risk management, and favorable regulatory impacts. The IMS integration is progressing well, and the company is raising its 2025 revenue outlook. Despite increased G&A expenses, the company's balanced model and platform enhancements provide significant opportunities. The market cap indicates a moderate reaction, leading to a 'Positive' prediction for stock price movement in the next two weeks.
PRVA Slides
Privia Health Q1 2026 slides show operational strength, earnings disappoint2026-05-07
Privia Health Q4 2025 slides: EBITDA surges 39%, guidance strong2026-02-26
Privia Health Q2 2025 slides: Strong growth and raised guidance, but shares plunge2025-08-07
Privia Health Q1 2025 slides: Strong growth and margin expansion fuel raised guidance2025-05-08
PRVA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
